Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg)(Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg))

概要

基本信息

药物类型

重组载体疫苗、治疗性疫苗

别名

Human papillomavirus vaccine、VicOryx、p16INK4a peptide vaccine

+ [3]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病泌尿生殖系统疾病+ [1]

在研适应症

肿瘤肛门肿瘤头颈部肿瘤+ [4]

非在研适应症

HPV相关癌症

原研机构

Ruprecht-Karls-Universität Heidelberg

在研机构

ORYX GmbH & Co. KGOryx Gmbh & Co

Ruprecht-Karls-Universität Heidelberg

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的临床试验

NCT02526316

/ Completed临床1期

Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer

The study will include 10 patients with HPV-associated ano-genital cancer (cervical, vulvar, vaginal, penile, anal) or HPV-associated head and neck cancer, who are planned to receive a cisplatin-based chemotherapy (alternatively a carboplatin-based chemotherapy may be selected by investigators choice). Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy. Concurrent radiation is allowed and should be documented. The vaccination schedule will be repeated up to a total of 3 cycles (= 6 months) or until progression or intolerable toxicity. If chemotherapy is withheld (e.g. for toxicity), vaccination treatment can be continued.

开始日期2015-06-01

申办/合作机构

ORYX GmbH & Co. KG

NCT01462838

/ Completed临床1/2期

Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers

Patients with advanced HPV- and p16INK4a-positive cancers will receive the peptide P16_37-63 in combination with Montanide® ISA-51 VG so that an immune response directed against the tumor cells can be induced. The aim is to show that vaccination with P16_37-63 is safe and can induce or enhance immune responses against p16INK4a.

开始日期2011-08-01

申办/合作机构

ORYX GmbH & Co. KG

100 项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的临床结果

登录后查看更多信息

100 项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的转化医学

登录后查看更多信息

100 项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的专利（医药）

登录后查看更多信息

425

项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Strategically striving to be more inclusive: A recommendation for gender-neutral human-papillomavirus vaccine policies

Article

作者: Van Loon, Katherine ; Nkya, Aslam ; Xu, Mary Jue ; Okerosi, Samuel

The World Health Organization (WHO) has shifted from a multiple-dose human papillomavirus (HPV) vaccine schedule to a one-dose schedule prioritizing females aged 9-14 y. Given the burden of HPV-associated disease aside from cervical cancer and affecting both sexes, a shift toward emphasizing gender-neutral HPV vaccination strategies may improve vaccination coverage and more comprehensively address HPV-driven disease across both sexes, particularly for low- and middle-income countries.

2025-04-01·Pediatrics

Improving Human Papillomavirus Vaccine Administration Using Medical-Dental Integration

Article

作者: Breslin, Kristin ; Podewils, Laura J. ; Hamilton, Scott ; Stein, Amy B. ; Williams, Joshua T. B. ; Jack, Jessica L.

BACKGROUND AND OBJECTIVESChildren aged 9 years and older visit dental providers more frequently than medical providers. Routine dental visits include screenings for human papillomavirus (HPV)–related oropharyngeal cancers and provide opportunities for HPV vaccination. The objective of this project was to implement a medical-dental integration (MDI) program to enhance HPV vaccine administration among children aged 9 to 17 years being seen at dental clinics.METHODSBetween June 1, 2021, and May 31, 2023, we conducted a quality improvement initiative at dental clinics within a large, integrated, safety-net health care system in Denver, Colorado. We implemented an MDI program in which dental professionals recommended the HPV vaccine and integrated medical staff administered the vaccine during the appointment. The primary outcome assessed was the HPV vaccine receipt on the same day as the dental visit. We used interrupted time series and multivariate regression models to assess the intervention’s effectiveness.RESULTSDuring the intervention period, this program reached 2781 dental visits, with 77% of children covered by Medicaid and 21% uninsured. Among them, 60% identified as Hispanic, 23% identified as Black, and 40% preferred to speak Spanish. Interrupted time series analysis revealed an immediate 9.8% improvement. The overall vaccination rate at eligible visits increased from 5.3% to 13.9% during the 1-year intervention. The adjusted odds ratio (aOR) of HPV vaccination at a dental visit was 4 times higher during the intervention (aOR, 4.37; 95% CI, 3.22–5.92) compared with preintervention.CONCLUSIONSMDI was an effective intervention to increase HPV vaccination rates at a safety-net health care system.

2025-04-01·Southern Medical Journal

Role of Race, Rurality, and Age in Human Papillomavirus Vaccine Initiation among US Women

Article

作者: Higginbotham, John C ; Wang, Hui ; Macander, Casey ; Henderson-Mitchell, Randi ; Das, Antara ; Jones, Graham M ; Galafassi, Marcelo ; Willaert, Alta

OBJECTIVESHuman papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with a lifetime prevalence of more than 80%. HPV is associated with cervical cancer, which affects thousands of US women each year. A vaccine was introduced in 2006 to mitigate the prevalence and mortality of HPV-associated cancers. Although HPV vaccine adherence has increased over time, disparities in vaccine uptake exist among adolescents, and likely within adult communities. This study explored the impact of race/ethnicity, rural classification, and age on vaccine initiation among adult women in the United States.METHODSThe final sample included N = 4666 females aged 18 to 43 years from the 2022 National Health Interview Survey. A logistic regression model explored the association of race/ethnicity, rural classification, and age with HPV vaccine initiation.RESULTSOnly 40.1% of our sample ever received an HPV vaccine. Urban residents were significantly more likely than rural residents to have ever gotten an HPV vaccine. Hispanic, Black, and Asian participants had significantly lower HPV vaccine initiation rates compared with their White counterparts. Finally, as age increased, HPV vaccine initiation decreased.CONCLUSIONSEfforts to increase HPV vaccine uptake for future generations of women and girls in the United States should focus on rural communities, as well as Black, Hispanic, and Asian racial minorities. Because so many women within our sample had not received any HPV vaccine, we must emphasize the importance of HPV testing and cervical cancer screening, especially among aging women.

100 项与 Human papillomavirus vaccine(Ruprecht-Karls-University of Heidelberg) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肛门肿瘤	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
头颈部肿瘤	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
阴茎肿瘤	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
宫颈癌	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
阴道肿瘤	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
外阴肿瘤	临床2期	德国	ORYX GmbH & Co. KG	2022-01-30
肿瘤	临床2期	-	Oryx Gmbh & Co	-
肿瘤	临床2期	-	Ruprecht-Karls-Universität Heidelberg	-
HPV相关癌症	药物发现	德国	ORYX GmbH & Co. KG	2011-08-01